In vitro platform for retinal toxicity assessment and disease modelling
Newcells Biotech Ltd. seek companies able to provide ocular compounds and corresponding in vivo/in vitro data, to validate their retinal pigmented epithelium (RPE) model.
What could the Solution be used for?
Newcells Biotech Ltd has developed an in vitro model of the RPE derived from healthy and diseased human induced pluripotent stem cell lines, opening up the potential to assess novel ocular compounds for safety and efficacy. This technology could better predict the outcome of these studies in the human eye and reduce the number of animals used to assess the toxicity of ocular drugs.
Need for collaboration
An end-user pharmaceutical company, or consortium of companies, able to provide ocular compounds and data with known in vivo/in vitro toxicity profiles, is sought to validate the model. In addition, input on assay endpoints of interest would ensure the model is developed to best match the needs of your internal preclinical decision flow.
3Rs impact assessment
Drug development programmes targeting diseases of the eye are increasing. Assessment of ocular toxicity and disease modelling is typically carried out in retinal explant models from the mouse, rat or pig, requiring 20 animals per compound. Newcells’ assay enables high volume screening of drugs, facilitating removal of unsuitable compounds early in drug development and avoiding the need to use any animals in subsequent screening.
For more information or to contact the Solution provider: https://nc3rs.org.uk/crackit/vitroplatform-retinal-toxicity-assessment-a...